Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.
Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowsi N, Foeldvari I, Frech T, Gordon JK, Hudson M, Johnson SR, Khanna D, McMahan Z, Merkel PA, Narain S, Nikpour M, Pauling JD, Ross L, Valenzuela Vergara AM, Vacca A. Baron M, et al. Among authors: ferdowsi n. J Scleroderma Relat Disord. 2019 Feb;4(1):17-27. doi: 10.1177/2397198318783926. Epub 2018 Jul 18. J Scleroderma Relat Disord. 2019. PMID: 30906878 Free PMC article.
Measures of disease status in systemic sclerosis: A systematic review.
Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M; Damage Index Working Group of the Scleroderma Clinical Trials Consortium. Tay T, et al. Among authors: ferdowsi n. Semin Arthritis Rheum. 2017 Feb;46(4):473-487. doi: 10.1016/j.semarthrit.2016.07.010. Epub 2016 Jul 29. Semin Arthritis Rheum. 2017. PMID: 27765344 Review.
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group. Ferdowsi N, et al. Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Ann Rheum Dis. 2019. PMID: 30928903
Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis.
Morrisroe K, Hansen D, Huq M, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hill C, Roddy J, Walker J, Proudman S, Nikpour M. Morrisroe K, et al. Among authors: ferdowsi n. Arthritis Care Res (Hoboken). 2020 Nov;72(11):1625-1635. doi: 10.1002/acr.24076. Arthritis Care Res (Hoboken). 2020. PMID: 31539207
Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis.
Hoa S, Bernatsky S, Baron M, Proudman S, Stevens W, Sahhar J, Wang M, Steele RJ; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Nikpour M, Hudson M. Hoa S, et al. Chest. 2021 Dec;160(6):2158-2162. doi: 10.1016/j.chest.2021.06.014. Epub 2021 Jun 18. Chest. 2021. PMID: 34153341 No abstract available.
23 results